Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Myelodysplastic Syndromes 5Neoplasms 4Leukemia, Myeloid, Acute 4Leukemia, Myelomonocytic, Chronic 3Carcinoma, Squamous Cell 3Primary Myelofibrosis 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Leukemia, Lymphocytic, Chronic, B-Cell 2Leukemia 2Head and Neck Neoplasms 2Cytopenia 2Anemia, Refractory, with Excess of Blasts 2Waldenstrom Macroglobulinemia 1Thrombocythemia, Essential 1Squamous Cell Carcinoma of Head and Neck 1Splenomegaly 1Solid Tumor 1Polycythemia Vera 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Multiple Myeloma 1Melanoma 1Malignant Neoplasmas 1Lymphoma, Mantle-Cell 1Leukemia, Hairy Cell 1Esophageal Squamous Cell Carcinoma 1Epidermolysis Bullosa Dystrophica 1

Interventions

Epoetin Alfa 53Darbepoetin alfa 38epoetin beta 12ferric carboxymaltose 11Lenalidomide 5Cyclophosphamide 5luspatercept 4fludarabine phosphate 4fludarabine 4Erythropoietin 4Cyclosporine 4Cisplatin 4Busulfan 4Blood Transfusion 4ACE-011 4peginesatide 3iron isomaltoside 1000 3hematide 3ferrous sulfate 3ferric gluconate 3Radiotherapy 3Iron-Dextran Complex 3Filgrastim 3Ferric Oxide, Saccharated 3Biopsy 3Antilymphocyte Serum 3thymoglobulin 2telapristone acetate 2ruxolitinib 2ferrous fumarate 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Anemia × ON 01910 × Clear all
NCT02730884 2020-08-07

Single-Arm Study of the Efficacy and Safety of Oral Rigosertib in Patients With Myelofibrosis (MF) and Anemia

M.D. Anderson Cancer Center

Phase 2 Terminated
3 enrolled 6 charts
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Leukemia, Splenomegaly, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡